Literature DB >> 23270094

Histological classification of liver and intrahepatic bile duct cancers in SEER registries.

Sean F Altekruse1, Susan S Devesa, Lois A Dickie, Katherine A McGlynn, David E Kleiner.   

Abstract

UNLABELLED: Clear definitions of histological groups are essential for studies of liver and intrahepatic bile duct cancers. Thus, we developed a classification system based on abstracted information on histologies of liver and intrahepatic bile duct cancers diagnosed during 1978-2007 within all Surveillance, Epidemiology, and End Results (SEER) registries. Of 61,990 reported primary liver and intrahepatic bile duct cancers, 108 distinct ICD-O histology codes were identified. During the 5 recent years of diagnosis, 2003-2007, the leading histological groups were hepatocellular carcinoma (75%) and cholangiocarcinoma (12%). The remaining categories were other specified (3%) and poorly specified carcinomas (3%), hepatoblastomas (1%), sarcomas (1%), embryonal sarcomas (0.1%), other specified malignancies (0.05%), and poorly specified malignancies (5%). During 2003-2007, only 68% of diagnoses were microscopically confirmed. Factors contributing to incomplete histological classification may include reluctance to obtain diagnostic specimens from late stage cases and administration of therapy in lieu of histological confirmation after positive diagnostic imaging.
CONCLUSION: The proposed histological classification in this report may facilitate studies of primary liver cancers. This is of value because the inconsistent characterization of some cancers, particularly cholangiocarcinomas, may affect interpretation of incidence trends. Incomplete histological characterization of hepatocellular carcinomas was noted in this report. It is likely to be explained by guidelines affirming the use of non-invasive diagnostic and treatment procedures for this cancer.

Entities:  

Mesh:

Year:  2011        PMID: 23270094      PMCID: PMC4148005     

Source DB:  PubMed          Journal:  J Registry Manag        ISSN: 1945-6131


  8 in total

1.  Protocol for the examination of specimens from patients with carcinoma of the intrahepatic bile ducts.

Authors:  Mary Kay Washington; Jordan Berlin; Philip A Branton; Lawrence J Burgart; David K Carter; Carolyn C Compton; Wendy L Frankel; J Milburn Jessup; Sanjay Kakar; Bruce Minsky; Raouf E Nakhleh; Jean-Nicolas Vauthey
Journal:  Arch Pathol Lab Med       Date:  2010-04       Impact factor: 5.534

2.  Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma.

Authors:  Eugene Leong; Wei Wen Chen; Evan Ng; Guy Van Hazel; Andrew Mitchell; Nigel Spry
Journal:  J Gastrointest Cancer       Date:  2012-03

Review 3.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 4.  Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 5.  Current approach to hepatocellular carcinoma.

Authors:  Peter Abrams; J Wallis Marsh
Journal:  Surg Clin North Am       Date:  2010-06-08       Impact factor: 2.741

Review 6.  Discerning tumor status from unstructured MRI reports--completeness of information in existing reports and utility of automated natural language processing.

Authors:  Lionel T E Cheng; Jiaping Zheng; Guergana K Savova; Bradley J Erickson
Journal:  J Digit Imaging       Date:  2009-05-30       Impact factor: 4.056

7.  Liver, gallbladder, extrahepatic bile ducts, and pancreas.

Authors:  M T Carriaga; D E Henson
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

  8 in total
  43 in total

1.  Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.

Authors:  Alicia C Smart; Lipika Goyal; Nora Horick; Natasa Petkovska; Andrew X Zhu; Cristina R Ferrone; Kenneth K Tanabe; Jill N Allen; Lorraine C Drapek; Motaz Qadan; Janet E Murphy; Christine E Eyler; David P Ryan; Theodore S Hong; Jennifer Y Wo
Journal:  Ann Surg Oncol       Date:  2019-12-23       Impact factor: 5.344

2.  Cancer Site-Specific Disparities in New York, Including the 1945-1965 Birth Cohort's Impact on Liver Cancer Patterns.

Authors:  Paulo S Pinheiro; Karen E Callahan; Francis P Boscoe; Raymond R Balise; Taylor R Cobb; David J Lee; Erin Kobetz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-19       Impact factor: 4.254

Review 3.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

4.  The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States.

Authors:  Vikrant V Sahasrabuddhe; Meredith S Shiels; Katherine A McGlynn; Eric A Engels
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

Review 5.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

6.  NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.

Authors:  Jessica L Petrick; Vikrant V Sahasrabuddhe; Andrew T Chan; Michael C Alavanja; Laura E Beane-Freeman; Julie E Buring; Jie Chen; Dawn Q Chong; Neal D Freedman; Charles S Fuchs; John Michael Gaziano; Edward Giovannucci; Barry I Graubard; Albert R Hollenbeck; Lifang Hou; Eric J Jacobs; Lindsay Y King; Jill Koshiol; I-Min Lee; Martha S Linet; Julie R Palmer; Mark P Purdue; Lynn Rosenberg; Catherine Schairer; Howard D Sesso; Alice J Sigurdson; Jean Wactawski-Wende; Anne Zeleniuch-Jacquotte; Peter T Campbell; Katherine A McGlynn
Journal:  Cancer Prev Res (Phila)       Date:  2015-09-21

7.  Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma.

Authors:  Christopher M Diehl; Amelia L Parker; Majda Haznadar; Kristopher W Krausz; Elise D Bowman; Siritida Rabibhadana; Marshonna Forgues; Vajarabhongsa Bhudhisawasdi; Frank J Gonzalez; Chulabhorn Mahidol; Anuradha Budhu; Xin W Wang; Mathuros Ruchirawat; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-07-29       Impact factor: 4.254

8.  Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma.

Authors:  Jian-Min Yuan; Menno Grouls; Steven G Carmella; Renwei Wang; Alisa Heskin; Yang Jiang; Yu-Ting Tan; Jennifer Adams-Haduch; Yu-Tang Gao; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2019-08-22       Impact factor: 4.944

9.  Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis.

Authors:  Jessica L Petrick; Jake E Thistle; Anne Zeleniuch-Jacquotte; Xuehong Zhang; Jean Wactawski-Wende; Alison L Van Dyke; Meir J Stampfer; Rashmi Sinha; Howard D Sesso; Catherine Schairer; Lynn Rosenberg; Thomas E Rohan; Kim Robien; Mark P Purdue; Jenny N Poynter; Julie R Palmer; Christina C Newton; Martha S Linet; Linda M Liao; I-Min Lee; Jill Koshiol; Cari M Kitahara; Jonathan N Hofmann; Barry I Graubard; Edward Giovannucci; Michael J Gaziano; Susan M Gapstur; Neal D Freedman; Dawn Q Chong; Andrew T Chan; Julie E Buring; Laura Beane E Freeman; Peter T Campbell; Katherine A McGlynn
Journal:  Am J Gastroenterol       Date:  2018-09-03       Impact factor: 10.864

10.  Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Authors:  Alison L Van Dyke; Meredith S Shiels; Gieira S Jones; Ruth M Pfeiffer; Jessica L Petrick; Jennifer L Beebe-Dimmer; Jill Koshiol
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.